An open-label, non-randomized, phase I clinical trial with resveratrol failed to increase frataxin levels in FRDA patients; however, high doses of resveratrol were associated with positive clinical outcomes (Yiu et al., 2015). This evidence concerns the gene FXN and Friedreich ataxia.